CN101973922A - Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor - Google Patents

Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor Download PDF

Info

Publication number
CN101973922A
CN101973922A CN 201010194233 CN201010194233A CN101973922A CN 101973922 A CN101973922 A CN 101973922A CN 201010194233 CN201010194233 CN 201010194233 CN 201010194233 A CN201010194233 A CN 201010194233A CN 101973922 A CN101973922 A CN 101973922A
Authority
CN
China
Prior art keywords
strontium
polymorphic form
solvate
preparation
compound shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 201010194233
Other languages
Chinese (zh)
Other versions
CN101973922B (en
Inventor
张和胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANJIN HEMEI BIOTECHNOLOGY CO Ltd
Original Assignee
TIANJIN HEMEI BIOTECHNOLOGY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIANJIN HEMEI BIOTECHNOLOGY CO Ltd filed Critical TIANJIN HEMEI BIOTECHNOLOGY CO Ltd
Priority to CN201210521245.XA priority Critical patent/CN102976996B/en
Priority to CN 201010194233 priority patent/CN101973922B/en
Publication of CN101973922A publication Critical patent/CN101973922A/en
Application granted granted Critical
Publication of CN101973922B publication Critical patent/CN101973922B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA an enzyme inhibitor. The invention discloses polymorphs HA, HB and HC or solvates of atorvastatin semi-strontium salt, which are shown as a formula (I). When used as HMG-CoA enzyme inhibitor medicines, the polymorphs HA, HB or HC, or the solvates of atorvastatin semi-strontium salt in the formula (I) are better choices for hypercalcemia syndrome, since the selected polymorphs HA, HB or HC, or the solvates of atorvastatin semi-strontium salt shown as the formula (I) not only can achieve the purpose of controlling blood cholesterol, but also can avoid the extra intake of calcium.

Description

Atorvastatin semi strontium salt polymorphic form, its preparation and as the HMG-CoA application of enzyme inhibitors
Technical field
The invention discloses atorvastatin semi strontium salt polymorphic form, its preparation method and as the HMG-CoA application of enzyme inhibitors.
Background of invention
The mechanism of action that statins reduces low-density lipoprotein in the body is clear and definite.The HMG-CoA enzyme can make HMG change into first hydroxyl penta salt, and this is the deciding step of biosynthesizing cholesterol in the liver.Extremely low low-density lipoprotein (VLDL) can be transferred to cholesterol in the liver and tri-glyceride in the outside cell.VLDL is decomposed release fat acid by outside cell.VLDL will be changed into the lipoprotein (IDL) of intermediate density so, and IDL can be shifted or be transformed into LDL by low-density lipoprotein (LDL) acceptor.The content of reducing cholesterol can increase the number and the corresponding amount that reduces the LDL that is changed by IDL of ldl receptor.By suppressing the HMG-CoA enzyme, statins can effectively be blocked cholesterol synthesizing in liver, thereby effectively reduces low-density lipoprotein.High LDL level can cause coronary heart disease, causes thrombus.Therefore, reduce low-density lipoprotein and can effectively prevent cardiovascular diseases, especially coronary heart disease or other hypercholesteremia syndromes.
Zarator (Atorvastatin, i.e. compound shown in the formula II) is a most popular kind in the statins.The earliest, (US-4681893 has mentioned the lactone of Zarator and its calcium salt forms in US-5273995) in the patent of the U.S..The atorvastatin semi-calcium salt trihydrate is by Pfizer called after Lipitor (LIPITOR), and 2007 annual sales amounts are above 12,000,000,000 dollars.
Figure GSA00000133352600011
The patent No. is: 2002/0099224; 5273995; 5298627; 5003080; 5097045; 5124482; 5149837 U.S. Patent Publication the preparation process of Zarator.Half calcium salt of Zarator is seen patent US-5273995.(US-5959156 discloses the I of atorvastatin semi-calcium salt, II, III, IV crystal formation in US-6121462) to United States Patent (USP).The V crystal formation of atorvastatin semi-calcium salt is announced in patent WO-01/36384.Other crystal formation of atorvastatin semi-calcium salt is at patent WO-02/43732, and WO-02/41834 announces among the WO-03/070702.
Single molecule can form various salt or crystal type, and as Zarator I type or its salt (II) type, because neighboring molecule intermolecular interaction and direction different in the crystal, the different salt or the polymorphic of same molecule can have different physical propertiess.An important physical properties of medicine is its solvability, especially can dissolve in gastric juice.The drug effect of medicine is relevant with the drug level that medicine can reach in blood, and same a part, the solubility property in gastric juice and intestinal juice directly influence medicine by the absorption of GI system.Thereby the salt or the crystal formation that have the medicine of proper solubility energy may have better result of treatment than slower salt or the crystal formation of dissolving.The atorvastatin semi-calcium salt trihydrate is water-soluble lower, and its oral administration biaavailability only is 12%.The highly water-soluble salt of research and development Zarator can improve the oral administration biaavailability of Zarator.Thereby salt or polymorphic form that the research and development Zarator is new are very valuable.
Usually, the salt that the metal ion that organic acid and nucleidic mass are big forms water-soluble lower than consanguinity low atomic weight metal cation salt is lower than the acetylsalicylic acid calcium salt such as acetylsalicylic acid barium salt water-soluble.Yet when our salt at the screening Zarator, what be surprised to find polymorphic HA, the HB of atorvastatin semi strontium salt and HC water-solublely is higher than commercially available atorvastatin semi-calcium salt trihydrate widely.
Summary of the invention
Correspondingly, the invention discloses polymorphic form HA, HB, HC or its solvate of compound shown in the formula I, the water-soluble of the polymorphic form HA of compound shown in the formula I disclosed by the invention or its solvate is 0.706mg/ml, the water-soluble of the polymorphic form HB of compound shown in the formula I or its solvate is 0.38mg/ml, the water-soluble of the polymorphic form HC of compound shown in the formula I or its solvate is 0.43mg/ml, under same testing method, the water-soluble of atorvastatin semi-calcium salt trihydrate only is 0.198mg/ml.Therefore, polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention, HC or its solvate are all much higher than atorvastatin semi-calcium salt trihydrate.
Figure GSA00000133352600021
The polymorphic form HA of compound shown in the formula I disclosed by the invention or the X-ray powder diffraction collection of illustrative plates of its solvate have following peak:
Angle of diffraction (2 θ, °) Intensity (I/I 0) Angle of diffraction (2 θ, °) Intensity (I/I 0)
?5.340 29.0 ?8.680 47.8
?18.339 100.0 ?18.739 74.7
?19.099 37.2 ?22.742 12.1
The polymorphic form HB of compound shown in the formula I disclosed by the invention or the X-ray powder diffraction collection of illustrative plates of its solvate have following peak:
Angle of diffraction (2 θ, °) Intensity (I/I 0) Angle of diffraction (2 θ, °) Intensity (I/I 0)
?8.639 83.9 ?9.842 33.4
?11.520 39.5 ?16.399 100
?17.619 15.4 ?19.986 24.5
?20.218 31.7 ?21.718 30.5
?29.860 12.3
The polymorphic form HC of compound shown in the formula I disclosed by the invention or the X-ray powder diffraction collection of illustrative plates of its solvate have following peak:
Angle of diffraction (2 θ, °) Intensity (I/I 0) Angle of diffraction (2 θ, °) Intensity (I/I 0)
?3.760 100.0 ?11.420 12.4
?7.662 24.8 ?16.359 17.8
?8.379 27.9 ?19.261 16.6
?9.381 15.3 ?19.678 24.1
Polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention or HC or its solvate provide the better choice of HMG-CoA enzyme inhibitors class medicine for hypercalcemia syndromes sufferer.Hypercalcemia patient need avoid the absorption of calcium as far as possible, to reduce because the harm that the raising of blood calcium concentration causes to its heart.Selecting for use polymorphic form HA, the HB of the compound shown in the formula I or HC or its solvate as HMG-CoA enzyme inhibitors class medicine, can reach the purpose of control blood cholesterol, can avoid the absorption of extra calcium again, is the optimal selection of this class sufferer.
The absorption of strontium ion can effectively improve the bone density of elderly woman after the elderly, especially climacterium.Thereby polymorphic form HA, the HB of compound shown in the formula I, HC or its solvate also have the drug effect of prevention elderly woman osteoporosis.
The invention also discloses the preparation method of polymorphic form HA, HB, HC or its solvate of compound shown in the formula I: at first, sodium salt, sylvite, ammonium or the ammonium carbamate of Zarator are dissolved in the suitable solvent to form the Zarator salts solution, and then adding contains the solution of strontium salt, stir to such an extent that separate out white or off-white color solid at-20 °~100 ℃ behind the settled solution, filter the dry atorvastatin semi strontium salt that gets.Described solvent can be any sodium salt that can dissolve Zarator, sylvite, the solvent of ammonium or ammonium carbamate, the kind difference of looking salt can make water, alcoholic solvent, ether solvent, amide solvent, ketones solvent, methyl-sulphoxide, esters solvent, the polyoxyethylene glycol kind solvent, include but not limited to methyl alcohol, ethanol, propyl alcohol, Virahol, the trimethyl carbinol, isopropylcarbinol, isopropyl ether, tetrahydrofuran (THF), dioxane, dimethyl formamide, ethanamide, N,N-dimethylacetamide, acetone, butanone, ethyl acetate, methyl acetate, ethyl formate, methyl-formiate, propyl acetate, isopropyl acetate, propyl formate, isopropyl formate, methyl propionate, ethyl propionate, methyl-butyrate, Macrogol 200, poly(oxyethylene glycol) 400, Polyethylene Glycol-600, cetomacrogol 1000, the polyoxyethylene glycol monoether, the polyoxyethylene glycol diether.Described strontium salt can be mineral acid strontium or organic acid strontium, includes but not limited to strontium nitrate, strontium chloride, Strontium Sulphate, strontium bisulfate, strontium phosphate, strontium monophosphate, sulfonic acid strontium, Strontium carbonate powder, strontium bicarbonate, strontium formate, strontium acetate, trifluoroacetic acid strontium, Succinic Acid strontium, strontium maleate, fumaric acid strontium, gluconic acid strontium, strontium tartrate, strontium salicylate.The described solution that contains strontium salt represents that organic acid strontium or mineral acid strontium are water-soluble, methyl alcohol, ethanol, propyl alcohol, Virahol, the trimethyl carbinol, isopropylcarbinol, isopropyl ether, tetrahydrofuran (THF), dioxane, dimethyl formamide, ethanamide, N,N-dimethylacetamide, acetone, butanone, ethyl acetate, methyl acetate, ethyl formate, methyl-formiate, propyl acetate, isopropyl acetate, propyl formate, isopropyl formate, methyl propionate, ethyl propionate, methyl-butyrate, Macrogol 200, poly(oxyethylene glycol) 400, Polyethylene Glycol-600, cetomacrogol 1000, the polyoxyethylene glycol monoether, the polyoxyethylene glycol diether, resulting solution in one or more the mixed solvent such as methyl-sulphoxide.
The second method of polymorphic form HA, HB, HC or its solvate of compound shown in the preparation formula I: the Zarator strontium is dissolved in the suitable solvent, stir to such an extent that add another kind of solvent behind the settled solution again and continue to stir and separate out white or off-white color solid at-20~100 ℃, filter the dry atorvastatin semi strontium salt finished product that gets.The suitable solvent of described dissolving Zarator is meant the solvent that the Zarator strontium is had better solubleness, include but not limited to one or more mixed solvent such as methyl alcohol, ethanol, propyl alcohol, Virahol, the trimethyl carbinol, isopropylcarbinol, tetrahydrofuran (THF), dimethyl formamide, ethanamide, N,N-dimethylacetamide, Macrogol 200, poly(oxyethylene glycol) 400, Polyethylene Glycol-600, cetomacrogol 1000, polyoxyethylene glycol monoether, polyoxyethylene glycol diether, methyl-sulphoxide.The another kind of solvent of described adding is selected from one or more the mixed solvent in water, isopropyl ether, dioxane, acetone, butanone, ethyl acetate, methyl acetate, ethyl formate, methyl-formiate, propyl acetate, isopropyl acetate, propyl formate, isopropyl formate, methyl propionate, ethyl propionate or the methyl-butyrate.
The third method of polymorphic form HA, HB, HC or its solvate of compound shown in the preparation formula I: Zarator is dissolved in the suitable solvent to form Zarator solution, and then the solution of adding Strontium carbonate powder, strontium bicarbonate or strontium hydroxide, stir to such an extent that separate out white or off-white color solid at-20 °~100 ℃ behind the settled solution, filter the dry atorvastatin semi strontium salt finished product that gets.Described solvent is selected from water, methyl alcohol, ethanol, propyl alcohol, Virahol, the trimethyl carbinol, isopropylcarbinol, isopropyl ether, tetrahydrofuran (THF), dioxane, dimethyl formamide, ethanamide, N,N-dimethylacetamide, acetone, butanone, ethyl acetate, methyl acetate, ethyl formate, methyl-formiate, propyl acetate, isopropyl acetate, propyl formate, isopropyl formate, methyl propionate, ethyl propionate, methyl-butyrate, Macrogol 200, poly(oxyethylene glycol) 400, Polyethylene Glycol-600, cetomacrogol 1000, the polyoxyethylene glycol monoether, the polyoxyethylene glycol diether, one or more mixed solvent such as methyl-sulphoxide.
Polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention, HC or its solvate can be one or more the mixture among polymorphic form HA, HB or the HC when the active constituents of medicine.
The formulation when the active constituents of medicine of polymorphic form HA, the HB of compound, HC or its solvate shown in the formula disclosed by the invention (I) can be and anyly can reach the formulation with therapeutic action, include but not limited to that solid dosage is (as tablet, powder, suppository, capsule, lozenge), suspension or pharmaceutical solutions.
Formulation when polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention, HC or its solvate are used as active constituents of medicine can be sustained release preparation.
Except polymorphic form HA, HB or HC or its solvate that contains compound shown in the formula I disclosed by the invention, but preparation contains polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention or HC or its solvate and learns as the formulation drug of choice of medicine and go up suitable pharmaceutical excipient, as derivatived cellulose, include but not limited to cellulose powder, Microcrystalline Cellulose, methylcellulose gum, ethyl cellulose, Natvosol, hydroxypropylcellulose, Vltra tears, carboxyethyl cellulose salt and other replace and substituted cellulose not; Starch; Pre-gelatinized starch; Can contain other additives commonly used in the pharmaceutical industry in addition, include but not limited to paraffin, sugar and sugar alcohol (as N.F,USP MANNITOL, sorbyl alcohol), polyacrylic ester and pectin, dextrin, gelatin; Weighting agent comprises tackiness agent, as gum arabic, pre-gelatinized starch, sodium alginate, glucose and other tackiness agents of using in granulation and compression; Used weighting agent can comprise disintegrating agent in compound, as primojel, and Povidone, low-substituted hydroxypropyl cellulose etc.; In addition, weighting agent also comprises tablet lubricant, seasonings, sweeting agent, sanitas; Capsule preparations can contain by gelatin or other conventional capsule materials; Tablet and powder can be prepared into the enteric film wrap sheet, and described enteric film can be made up of in the multipolymer of the multipolymer of cellulose acetate-phthalate, hydroxypropylmethylcellulose phthalate, polyvinyl alcohol phthalic acid, vinylbenzene and toxilic acid or methacrylic acid and methyl methacrylate one or more.
Polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention or HC or its solvate can be 0.5mg-200mg as the unit using dosage of medicine; Preferred unit using dosage is 2.5mg-80mg; Most preferred unit using dosage is 10mg-80mg; The unit using dosage of most convenient is 10mg, 20mg, and 40mg, 80mg, and can take this medicine of one or many in one day.
Unit using dosage described in the present invention is meant the unit that can be applied to patient and easy handling and packing, promptly single dosage.
Polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention or HC or its solvate can be used as preparation HMG-CoA enzyme inhibitor medicine, being used for the treatment of can be improved physically different by suppressing the HMG-CoA enzyme, includes but not limited to that disease, low-density lipoprotein white level that coronary heart disease, thrombosis cause improve disease or the hypercholesterolemia that causes.
Polymorphic form HA, the HB of compound shown in the formula I disclosed by the invention or HC or its solvate can be used for preparing the medicine for the treatment of osteoporosis.
Description of drawings: Fig. 1: atorvastatincalcuim typical curve
Fig. 2: the polymorphic form HA of compound shown in the formula I or the X powder diffraction collection of illustrative plates of its solvate
Fig. 3: the polymorphic form HB of compound shown in the formula I or the X powder diffraction collection of illustrative plates of its solvate
Fig. 4: the polymorphic form HC of compound shown in the formula I or the X powder diffraction collection of illustrative plates of its solvate
Specific embodiment
Abbreviation language: THF: tetrahydrofuran (THF); MP: fusing point.
The measuring condition of X-ray powder diffraction collection of illustrative plates is as follows among the present invention:
Sample size: about 100mg
Target: Cu
Filter disc: monochrome
Voltage/current: 40kV/100mA
1 ° of slit: SS/DS, RS 0.3mm
Sweep velocity: 8 °/minute
Embodiment 1:
The aqueous solution that the aqueous solution of strontium nitrate (1.83g) is at room temperature added atorvastatin sodium (10g), stirring at room is to separating out solid, suction filtration is collected solid, washes filter cake with 100ml, filter cake is put into the polymorphic form HA that obtains atorvastatin semi strontium salt after vacuum drying oven (40 ℃) drying.MP:202-212 ℃ of decomposition, aes determination content of strontium 6.7%, MS:557 (M-1).Water-soluble: 0.7mg/ml.
Embodiment 2:
5g Zarator ammonium is dissolved in THF, at room temperature adds the aqueous solution of strontium acetate (1.75g), stirring at room is to separating out solid, and suction filtration is collected solid, washes filter cake with 50ml, obtains atorvastatin semi strontium salt after filter cake is put into vacuum drying oven (40 ℃) drying.MP:201-205 ℃ of decomposition, aes determination content of strontium 6.6%.
Embodiment 3:
The methanol solution that the methanol solution of methylsulfonic acid strontium (1.2g) is at room temperature added atorvastatin sodium (5g), stirring at room is to separating out solid, suction filtration is collected solid, washes filter cake with 40ml, obtains atorvastatin semi strontium salt after filter cake is put into vacuum drying oven (40 ℃) drying.MP:203-206 ℃ of decomposition, aes determination content of strontium 6.7%.
Embodiment 4:
The 4.4g Zarator is dissolved in acetone, at room temperature adds the aqueous solution of strontium bicarbonate, stirring at room is to separating out solid, and suction filtration is collected solid, washes filter cake with 40ml, obtains atorvastatin semi strontium salt after filter cake is put into vacuum drying oven (40 ℃) drying.MP:202-210 ℃ of decomposition, aes determination content of strontium 6.9%.
Embodiment 5:
The 4.4g Zarator is dissolved in THF, at room temperature adds the aqueous solution of strontium acetate (3.5g), stirring at room is to separating out solid, and suction filtration is collected solid, washes filter cake with 50ml, obtains atorvastatin semi strontium salt after filter cake is put into vacuum drying oven (40 ℃) drying.MP:203-209 ℃ of decomposition, aes determination content of strontium 7.1%.
Embodiment 6:
(the water: THF=2: 1) in the solution that the aqueous solution of 18.28g strontium nitrate is at room temperature added atorvastatin sodium (100.51g), be stirred to and separate out solid, suction filtration is collected solid, water 1000ml stirred filter cake 2 hours, suction filtration is collected solid, the polymorphic form HB that obtains atorvastatin semi strontium salt after vacuum drying oven (50 ℃) drying put into filter cake by water (400ml * 3) filter wash cake.
Embodiment 7:
The polymorphic form HA of atorvastatin semi strontium salt is placed for a long time the polymorphic form HB that (including but not limited to the room temperature placement) can be converted into atorvastatin semi strontium salt.
Embodiment 8:
Get (4R-cis)-6-[2-[2-(4-fluorophenyl)-5-(1-sec.-propyl)-3-phenyl-4-[(aniline) carbonyl]-1H-pyrroles-1-yl] ethyl]-2,2-dimethyl-1,3-dioxane-4-tert.-butyl acetate 20g adds 200ml methyl alcohol and places stirring at room, get the 2.6ml concentrated hydrochloric acid and be dissolved in the 20ml water, keep being stirred to finishing reaction.
Keeping temperature to stir adding in solution down 10%NaOH solution to keep system pH is 12 to finishing reaction.Suction filtration keeps filtrate.Gained filtrate decompression vacuum concentration to about 130ml, is added anhydrous methanol, the mixing solutions of methyl tertiary butyl ether and water, the extraction separatory keeps water; Water adds methyl tertiary butyl ether again to be washed once, and separatory keeps water.Is 8 with 6N HCl regulation system pH value with gained solution under stirring at room, and vacuum rotary steam concentrates removes residual organic solvents.
Place 45 ℃ of oil baths to stir gained solution, getting the 4.214g strontium nitrate is dissolved in the 20ml water, under mechanical stirring, slowly splash into, drip to finish and to close heating and continue to stir centrifugal gained solution behind the 2h, the washing of gained filter cake once, keep the dry about 13h of 50 ℃ of reduced vacuum, get crude product atorvastatin strontium 15.1g.
Get gained crude product atorvastatin strontium 5g, add 25ml methyl alcohol and 25ml tetrahydrofuran (THF), ultrasonic or heating in water bath makes it dissolving, and suction filtration keeps filtrate, places 45 ℃ of oil baths to stir, and treats to add lentamente behind the temperature-stable water of 75ml, and solid is slowly separated out.After waiting to separate out solid, maintenance stirs 3h.Centrifugal gained solution, filter cake is washed once, and 50 ℃ of dry about 13h of reduced vacuum get 3.6g atorvastatin hemi strontium salt crystal formation HC.
The solubility test of atorvastatin semi calcium trihydrate and atorvastatin semi strontium salt polymorphic form HA, HB and HC
1. the foundation of typical curve
1) be that standard substance is done typical curve with atorvastatin semi calcium trihydrate
2) to get atorvastatin semi calcium trihydrate 4.59mg and place the 100ml volumetric flask, dissolving back constant volume. this moment, strength of solution was 0.0459mg/ml.
3) getting concentration more respectively is that Zarator calcium solution 5ml, 10ml, the 25ml of 0.0459mg/ml is settled to 50ml; Strength of solution is respectively 0.00459mg/ml, 0.00918mg/ml, 0.02295mg/ml.
4) getting its maximum absorption wavelength through uv scan is 241nm.
5) under 241nm, do typical curve and see accompanying drawing.
2. the solubility test of atorvastatin semi calcium trihydrate and atorvastatin semi strontium salt
1) prepares atorvastatin semi calcium trihydrate and atorvastatin semi strontium salt saturated solution respectively.
2) described saturated solution is filtered, get clear filtrate.
3) the gained clear filtrate is diluted to suitable multiple, makes its concentration readings in standard curve range.
4) measure absorbancy at the 241nm wavelength, draw concentration, calculate solubleness via typical curve.
3. measurement result:
The saturation solubility of atorvastatin semi calcium trihydrate: 0.1988mg/ml,
The saturation solubility of atorvastatin semi strontium salt polymorphic form HA: 0.70mg/ml,
The saturation solubility of atorvastatin semi strontium salt polymorphic form HB: 0.38mg/ml,
The saturation solubility of atorvastatin semi strontium salt polymorphic form HC: 0.43mg/ml.

Claims (11)

1. polymorphic form HA, the HB of compound or HC or its solvate shown in the formula (I), preparation method and the application in preparation HMG-CoA enzyme inhibitors class medicine
Figure FSA00000133352500011
2. the polymorphic form HA of compound or its solvate shown in claim 1 Chinese style (I), the X-ray powder diffraction collection of illustrative plates that it is characterized by described polymorphic form HA has following peak:
Angle of diffraction (2 θ, °) Intensity (I/I 0) Angle of diffraction (2 θ, °) Intensity (I/I 0) ?5.340 29.0 ?8.680 47.8 ?18.339 100.0 ?18.739 74.7 ?19.099 37.2 ?22.742 12.1
3. the polymorphic form HB of compound or its solvate shown in claim 1 Chinese style (I), the X-ray powder diffraction collection of illustrative plates that it is characterized by described polymorphic form HB has following peak:
Angle of diffraction (2 θ, °) Intensity (I/I 0) Angle of diffraction (2 θ, °) Intensity (I/I 0) ?8.639 83.9 ?9.842 33.4 ?11.520 39.5 ?16.399 100 ?17.619 15.4 ?19.986 24.5 ?20.218 31.7 ?21.718 30.5 ?29.860 12.3
4. the polymorphic form HC of compound or its solvate shown in claim 1 Chinese style (I), the X-ray powder diffraction collection of illustrative plates that it is characterized by described polymorphic form HC has following peak:
Angle of diffraction (2 θ, °) Intensity (I/I 0) Angle of diffraction (2 θ, °) Intensity (I/I 0)
?3.760 100.0 ?11.420 12.4 ?7.662 24.8 ?16.359 17.8 ?8.379 27.9 ?19.261 16.6 9.381 15.3 19.678 24.1
5. prepare the method for polymorphic form HA, HB, HC or its solvate of compound shown in claim 1,2,3 or 4 each Chinese styles (I), it is characterized in that described method is: the sodium salt of Zarator, sylvite, ammonium salt or ammonium carbamate make with the strontium reactant salt in suitable solvent.
6. prepare the method for polymorphic form HA, HB, HC or its solvate of compound shown in claim 1,2,3 or 4 each Chinese styles (I), it is characterized in that described method is: Zarator makes with Strontium carbonate powder, strontium bicarbonate or strontium hydroxide reaction in suitable solvent.
7. the method for polymorphic form HA, HB, HC or its solvate of compound shown in the preparation claim 1,2 in the claim 5,3 or 4 Chinese styles (I) is characterized in that described strontium salt is: strontium nitrate, strontium chloride, Strontium Sulphate, strontium bisulfate, strontium phosphate, strontium monophosphate, sulfonic acid strontium, Strontium carbonate powder, strontium bicarbonate, strontium formate, strontium acetate, trifluoroacetic acid strontium, Succinic Acid strontium, strontium maleate, fumaric acid strontium, gluconic acid strontium, strontium tartrate or strontium salicylate.
8. polymorphic form HA, HB, HC or its solvate application in being prepared into HMG-CoA enzyme inhibitors class medicine of compound shown in claim 1,2,3 or 4 each Chinese styles (I) is characterized in that being prepared into the suitable preparation that is used for the treatment of hypercholesterolemia by polymorphic form HA, HB, HC or its solvate and the appropriate formulation auxiliary material of compound shown at least a formula (I).
9. polymorphic form HA, HB, HC or its solvate of compound shown in claim 1,2,3 or 4 each Chinese styles (I) are being prepared into the application that improves in the bone density class medicine, it is characterized in that being prepared into the suitable preparation that is used for the treatment of osteoporosis by polymorphic form HA, the HB of compound shown at least a formula (I) or HC or its solvate and appropriate formulation auxiliary material.
10. the preparation of polymorphic form HA, the HB of compound shown in claim 9 or 10 Chinese styles (I), HC or the preparation of its solvate is characterized in that described preparation is tablet, powder agent, capsule, aqua, emulsion, suspensoid.
11. the preparation of polymorphic form HA, the HB of compound shown in claim 9 or 10 Chinese styles (I), HC or the preparation of its solvate, the unit using dosage scope that it is characterized in that described preparation is for containing polymorphic form HA, HB or HC or its solvate 0.5mg-200mg of compound shown in the formula (I).
CN 201010194233 2009-05-27 2010-05-25 Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor Expired - Fee Related CN101973922B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201210521245.XA CN102976996B (en) 2009-05-27 2010-05-25 Atorvastatin semi strontium salt polymorphic form, its preparation and the application as HMG-CoA enzyme inhibitors
CN 201010194233 CN101973922B (en) 2009-05-27 2010-05-25 Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN200910069038.3 2009-05-27
CN200910069038 2009-05-27
CN200910147819 2009-06-15
CN200910147819.X 2009-06-15
CN200910215281.1 2009-12-30
CN200910215281 2009-12-30
CN 201010194233 CN101973922B (en) 2009-05-27 2010-05-25 Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2012105212638A Division CN102976997A (en) 2009-05-27 2010-05-25 Polymorphic substance of atorvastatin semi-strontium salt as well as preparation method and application of polymorphic substance as HMG-CoA (Hydroxy Methylglutaryl Coenzyme A) enzyme inhibitor
CN201210521245.XA Division CN102976996B (en) 2009-05-27 2010-05-25 Atorvastatin semi strontium salt polymorphic form, its preparation and the application as HMG-CoA enzyme inhibitors

Publications (2)

Publication Number Publication Date
CN101973922A true CN101973922A (en) 2011-02-16
CN101973922B CN101973922B (en) 2013-01-23

Family

ID=43573840

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2012105212638A Pending CN102976997A (en) 2009-05-27 2010-05-25 Polymorphic substance of atorvastatin semi-strontium salt as well as preparation method and application of polymorphic substance as HMG-CoA (Hydroxy Methylglutaryl Coenzyme A) enzyme inhibitor
CN 201010194233 Expired - Fee Related CN101973922B (en) 2009-05-27 2010-05-25 Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor
CN201210521245.XA Active CN102976996B (en) 2009-05-27 2010-05-25 Atorvastatin semi strontium salt polymorphic form, its preparation and the application as HMG-CoA enzyme inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2012105212638A Pending CN102976997A (en) 2009-05-27 2010-05-25 Polymorphic substance of atorvastatin semi-strontium salt as well as preparation method and application of polymorphic substance as HMG-CoA (Hydroxy Methylglutaryl Coenzyme A) enzyme inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210521245.XA Active CN102976996B (en) 2009-05-27 2010-05-25 Atorvastatin semi strontium salt polymorphic form, its preparation and the application as HMG-CoA enzyme inhibitors

Country Status (1)

Country Link
CN (3) CN102976997A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273995A (en) * 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
US6605729B1 (en) * 2001-06-29 2003-08-12 Warner-Lambert Company Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2005123193A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
WO2008093951A1 (en) * 2007-01-29 2008-08-07 Hanmi Pharm. Co., Ltd. Atorvastatin strontium salt and pharmaceutical composition comprising same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20014746D0 (en) * 2001-09-28 2001-09-28 Clas M Kjoelberg Pain reliever
CN1795003A (en) * 2003-03-27 2006-06-28 桑托索尔夫公司 Anti-inflammatory composition based on strontium compounds
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
JP2008517992A (en) * 2004-10-28 2008-05-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Method for forming amorphous atorvastatin
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273995A (en) * 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
US6605729B1 (en) * 2001-06-29 2003-08-12 Warner-Lambert Company Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2005123193A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
WO2008093951A1 (en) * 2007-01-29 2008-08-07 Hanmi Pharm. Co., Ltd. Atorvastatin strontium salt and pharmaceutical composition comprising same

Also Published As

Publication number Publication date
CN101973922B (en) 2013-01-23
CN102976996A (en) 2013-03-20
CN102976997A (en) 2013-03-20
CN102976996B (en) 2015-08-19

Similar Documents

Publication Publication Date Title
AU2010222658B2 (en) Use of rosuvastatin lactols as medicaments
CN105669597B (en) Amyloid bonding agent
JP2003514798A (en) Polymorphism of atorvastatin calcium
AU2014370697B2 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
KR20130062947A (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
CA2505968C (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CN110200955A (en) The iso- α acid derivative of tetrahydro, composition and method
EP3680232A1 (en) NOVEL ANTHRANILIC ACID-BASED COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME
RU2468015C2 (en) Polymorphic forms of deferasirox (icl670a)
WO2005121112A1 (en) Medicinal compositions containing 6-hydroxybenz- bromarone or salts thereof
Bandgar et al. Synthesis and biological evaluation of ester prodrugs of benzafibrate as orally active hypolipidemic agents
CN106279126A (en) Afatinib acid-addition salts and crystal formation, its preparation method and pharmaceutical composition
CN101973922B (en) Atorvastatin semi-strontium salt polymorphs as well as preparation and application thereof as HMG-CoA enzyme inhibitor
JP2002538202A (en) Dihydroxy open acid of HMG-CoA reductase inhibitor and salt thereof
CN102718735A (en) 2-ethyl-3-(4-hydroxy) benzoyl benzofuran compounds and compositions and preparation methods of compounds
JP2022505033A (en) Gemkaben, its pharmaceutically acceptable salt, its composition, and how to use it
CN109422784B (en) Salidroside derivative and preparation method and application thereof
JP2004508347A (en) Dihydroxy ring-opening salt of simvastatin
SK10622002A3 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
CN104955816B (en) Crystal formation that a kind of Ansai is bent and preparation method thereof, its pharmaceutical composition and purposes
CN101538237B (en) Atorvastatin semi-calcium salt butanone co-crystallization substances, preparation and application thereof as HMG-CoA enzyme inhibitor
EP3842410A1 (en) Fibric acid compound and medical use thereof
WO2010029561A1 (en) A process for preparation of rosuvastatin acetonide calcium
CN105294578A (en) Quinazoline derivative having targeted antitumor activity
CN102838652B (en) A kind of oleanolic acid derivate with anticarcinogenesis and its production and use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130123

Termination date: 20160525

CF01 Termination of patent right due to non-payment of annual fee